Study	Reason for exclusion
Ashworth 2008	Review article
Audeh 2009	Phase II, single‐arm trial of the oral PARP inhibitor OLA (AZD2281) in BRCA‐deficient advanced ovarian cancer (ASCO 2009 meeting abstract)
Audeh 2010	Non‐randomised, phase II, single‐arm study (update of Audeh 2009)
Banerjee 2013	Review article
Chen 2013	Review article
Coleman 2014	Non‐randomised phase II trial; no control group
Drew 2008	Review article
Fong 2006	Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly(ADP‐ribose) polymerase (PARP), KU‐0059436 (Ku) in patients with advanced tumours (ASCO 2006 meeting abstract)
Fong 2008	Results from a phase I study of AZD2281 (KU‐0059436), a PARP (poly(ADP‐ribose) polymerase) inhibitor with single‐agent anticancer activity in patients with BRCA‐deficient ovarian cancer (ASCO 2008 meeting abstract)
Fong 2009	Non‐randomised phase I clinical trial analysing the pharmacokinetic and pharmacodynamic characteristics of OLA (AZD2281). Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation
Gelmon 2011	Phase 2, multicentre, open‐label, non‐randomised study
Helleday 2008	Review article
Lee 2014	Biomarker study of RCT comparing olaparib plus/minus cediranib: wrong comparison and wrong outcomes
Lord 2008	Review article
Lui 2014	Comparison of Olaparib versus Olaparib and Cediranib ‐ no randomisation of Olaparib; 2 references to this study.
Moore 2014	On‐going study but study on effects of high fat food on pharmacokinetics
Muggia 2009	Review article
NCT01891344	Ongoing, non‐randomised, open‐label, phase II study (Ariel2)
Shaw 2013	Review article
Turner 2005	Review article
Yap 2007	Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU‐0059436 (Ku), a small molecule inhibitor of poly(ADP‐ribose) polymerase (PARP) in cancer patients, including BRCA1/2 mutation carriers (ASCO 2007 meeting abstract)
Yap 2009	Review article

OLA: olaparib